Qiagen Submits Second PMA for Therascreen KRAS Companion Dx

The firm completed a submission to FDA for use of the test as a companion to Erbitux, a monoclonal antibody EGFR inhibitor with sales last year of $820 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories